NOVEL THERAPY FOR PANCREATIC CANCERS, TARGETING MOLECULAR FOUNDATION
Dr Michael KC Lee,
Medical Oncologist,
Peter MacCallum Cancer Centre,
Melbourne, Australia
RESEARCHER PROFILE
Filmed in Melbourne, Australia | February 2026
Dr Michael Lee is an experienced medical oncologist, sub-specialising in gastrointestinal cancers and neuroendocrine tumours at the Peter MacCallum Cancer Centre.
He plays a key role in molecular tumour boards at VCCC Alliance (Victorian Comprehensive Cancer Centre) and MPCCC (Monash Partners Comprehensive Cancer Consortium), ensuring the accurate and effective use of precision medicine in cancer care across the state.
His care philosophy, embodied in his practice name, “Can-Therapy,” promotes a CAN-do approach to CANcer care: empowering patients to thrive beyond cancer through cutting-edge research and personalised, values-driven care. Beyond the clinic, he leads research as a clinician scientist, developing therapeutic strategies that target RNA processing – the molecular blueprint cancer hijacks to fuel its growth and resistance – by altering its sequence is like changing words in a sentence to redefine cancer’s trajectory.
Supported by Pancare Foundation, the Paul Dear Post Doctoral Fellowship and his industry collaboration, his work aims to revolutionise outcomes for patients with this aggressive cancer by targeting its molecular foundation.
He is a recognised expert in pancreatic cancer care, combining research insights with exceptional patient care, while also providing comprehensive treatment for all cancer types.
Source: Supplied
https://orcid.org/0000-0001-8075-3608
-
World-first clinical trial improves patient outcomes for kidney transplants (2023)
A world-first clinical trial conducted at the Royal Adelaide Hospital (RAH) and at hospitals across Australia and New Zealand has identified the best fluid treatment to reduce the risk of patients requiring dialysis after a kidney transplant.
Around one in three people who receive a kidney transplant suffer delayed graft function, which means the transplant doesn’t work immediately and they require dialysis.
The lead-author of the study, was Royal Adelaide Hospital Nephrologist and University of Adelaide researcher, Dr Michael Collins.
-
Understanding the experience of pain for novel brain-based treatments
Associate Professor Tasha Stanton leads the Persistent Pain Research Group at SAHMRI. She is also co-Director of IIMPACT in Health at the University of South Australia, Adelaide. She is a clinical pain neuroscientist, with original training as a physiotherapist, and her research focusses on pain – why do we have it and why doesn’t it go away?
-
Blister management and impact on firefighters
David Burns, a Senior Paramedic with LifeAid, a private paramedicine company in Victoria and, has a diverse background in healthcare. He began his career as a registered nurse, progressing to critical care nursing specialising in liver transplants and cardiovascular surgery.
At the Australasian College of Paramedicine International Conference, David presented research focused on the foot care of firefighters during prolonged bushfire campaigns. During the 2019-2020 bushfires, over 10,000 firefighters sought care, with nearly 50% requiring attention for foot-related issues. David emphasised that inadequate foot care could bench firefighters for up to 10 days, diminishing their ability to protect communities and critical infrastructure. Recognising the economic benefits of prioritising firefighter health, David advocates that ensuring their well-being allows communities to recover effectively and enhances safety for all involved in firefighting efforts.
